Lexicon Pharmaceuticals (LXRX) Other Operating Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Other Operating Expenses data on file, last reported at $108000.0 in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 260.0% year-over-year to $108000.0 in Q1 2026; TTM through Mar 2026 was $352000.0, a 42.76% decrease from a year earlier, with the FY2025 full-year figure at $274000.0, down 55.52% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $108000.0, down from $201000.0 in the prior quarter.
• Over the last five years, Other Operating Expenses for LXRX reached as high as $10.7 million in Q2 2022 and fell as low as $7000.0 in Q3 2023.
• Historically, Other Operating Expenses has averaged $1.4 million across 5 years, with a median of $70500.0 in 2023.
• Across the five-year window, Other Operating Expenses tumbled 99.93% in 2023 and surged 1975.0% in 2024, its largest moves.
• Year by year, Other Operating Expenses stood at $10.7 million in 2022, then sank by 99.34% to $70000.0 in 2023, then surged by 397.14% to $348000.0 in 2024, then slumped by 42.24% to $201000.0 in 2025, then slumped by 46.27% to $108000.0 in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $108000.0 in Q1 2026, $201000.0 in Q4 2025, and $10000.0 in Q3 2025.